On Tuesday, Cytek BioSciences Inc (NASDAQ: CTKB) opened lower -3.33% from the last session, before settling in for the closing price of $3.30. Price fluctuations for CTKB have ranged from $2.37 to $7.63 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 28.20% over the last five years. Company’s average yearly earnings per share was noted -217.32% at the time writing. With a float of $114.61 million, this company’s outstanding shares have now reached $127.60 million.
The firm has a total of 648 workers. Let’s measure their productivity. In terms of profitability, gross margin is 54.94%, operating margin of -12.57%, and the pretax margin is -4.05%.
Cytek BioSciences Inc (CTKB) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of Cytek BioSciences Inc is 9.52%, while institutional ownership is 60.95%. The most recent insider transaction that took place on Jun 02 ’25, was worth 97,300. In this transaction Chief Financial Officer of this company bought 35,000 shares at a rate of $2.78, taking the stock ownership to the 55,746 shares.
Cytek BioSciences Inc (CTKB) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -217.32% per share during the next fiscal year.
Cytek BioSciences Inc (NASDAQ: CTKB) Trading Performance Indicators
Check out the current performance indicators for Cytek BioSciences Inc (CTKB). In the past quarter, the stock posted a quick ratio of 4.95. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.05. Likewise, its price to free cash flow for the trailing twelve months is 23.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.09, a number that is poised to hit -0.04 in the next quarter and is forecasted to reach -0.07 in one year’s time.
Technical Analysis of Cytek BioSciences Inc (CTKB)
Analysing the last 5-days average volume posted by the [Cytek BioSciences Inc, CTKB], we can find that recorded value of 1.26 million was better than the volume posted last year of 0.97 million. As of the previous 9 days, the stock’s Stochastic %D was 36.07%. Additionally, its Average True Range was 0.20.
During the past 100 days, Cytek BioSciences Inc’s (CTKB) raw stochastic average was set at 22.53%, which indicates a significant decrease from 58.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.68% in the past 14 days, which was higher than the 72.34% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.30, while its 200-day Moving Average is $4.95. Now, the first resistance to watch is $3.29. This is followed by the second major resistance level at $3.40. The third major resistance level sits at $3.49. If the price goes on to break the first support level at $3.09, it is likely to go to the next support level at $3.00. Now, if the price goes above the second support level, the third support stands at $2.89.
Cytek BioSciences Inc (NASDAQ: CTKB) Key Stats
There are currently 126,659K shares outstanding in the company with a market cap of 404.04 million. Presently, the company’s annual sales total 200,450 K according to its annual income of -6,020 K. Last quarter, the company’s sales amounted to 41,460 K and its income totaled -11,400 K.
